Obesity is a major health problem in the U.S. However, how adipose tissue disorders cause insulin resistance and related metabolic diseases is not known. Study of single gene disorders of adipose tissue may elucidate the mechanisms involved in these processes. Congenital generalized lipodystrophy (CGL) is an autosomal recessive disorder that results in almost complete absence of adipose tissue. Familial partial lipodystrophy, Dunnigan variety (FPLD) is an autosomal dominant disorder characterized by gradual loss of subcutaneous adipose tissue in both the upper and lower extremities during early adolescence, and excessive adipose tissue on the face and neck. Other common features include insulin resistance, diabetes mellitus, hypertriglyceridemia, low levels of high density lipoprotein, acanthosis nigricans and in some women, hirsutism and menstrual abnormalities. The genetic basis and pathophysiology of the metabolic complications in these disorders is not known. The project therefore has two aims: 1) to characterize metabolic abnormalities in patients with CGL and FPLD and 2) to identify the molecular basis of these disorders. To accomplish these aims, we have collected a number of well-characterized pedigrees. We will study body fat distribution by anthropometry and whole body magnetic resonance imaging and will measure insulin sensitivity, plasma lipoproteins, free fatty acids, glycerol and other metabolic variables. We have localized the FPLD gene to chromosome 1q21-22 by genome-wide linkage analysis. Similar studies are underway to localize the gene for CGL. Following chromosomal localization and fine mapping, candidate genes, already mapped or identified by positional cloning into these regions will be examined for mutations using the single strand conformation polymorphism (SSCP), denaturing high performance liquid chromatography (DHPLC) or direct sequencing. The identification of gene defects will allow us to define the normal role of these genes in insulin action and body fat distribution and will lead to a better understanding of how common adipose tissue disorders such as obesity cause insulin resistance and other metabolic complications.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
5R01DK054387-02
Application #
6177971
Study Section
Metabolism Study Section (MET)
Program Officer
Mckeon, Catherine T
Project Start
1999-05-15
Project End
2003-03-31
Budget Start
2000-04-01
Budget End
2001-03-31
Support Year
2
Fiscal Year
2000
Total Cost
$378,614
Indirect Cost
Name
University of Texas Sw Medical Center Dallas
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Dallas
State
TX
Country
United States
Zip Code
75390
Agarwal, Anil K; Tunison, Katie; Dalal, Jasbir S et al. (2017) Metabolic, Reproductive, and Neurologic Abnormalities in Agpat1-Null Mice. Endocrinology 158:3954-3973
Agarwal, Anil K; Tunison, Katie; Dalal, Jasbir S et al. (2016) Mogat1 deletion does not ameliorate hepatic steatosis in lipodystrophic (Agpat2-/-) or obese (ob/ob) mice. J Lipid Res 57:616-30
Sankella, Shireesha; Garg, Abhimanyu; Agarwal, Anil K (2016) Characterization of the Mouse and Human Monoacylglycerol O-Acyltransferase 1 (Mogat1) Promoter in Human Kidney Proximal Tubule and Rat Liver Cells. PLoS One 11:e0162504
Cautivo, Kelly M; Lizama, Carlos O; Tapia, Pablo J et al. (2016) AGPAT2 is essential for postnatal development and maintenance of white and brown adipose tissue. Mol Metab 5:491-505
Garg, Abhimanyu; Kircher, Martin; Del Campo, Miguel et al. (2015) Whole exome sequencing identifies de novo heterozygous CAV1 mutations associated with a novel neonatal onset lipodystrophy syndrome. Am J Med Genet A 167A:1796-806
Patni, Nivedita; Alves, Crésio; von Schnurbein, Julia et al. (2015) A Novel Syndrome of Generalized Lipodystrophy Associated With Pilocytic Astrocytoma. J Clin Endocrinol Metab 100:3603-6
Garg, Abhimanyu; Xing, Chao (2014) De novo heterozygous FBN1 mutations in the extreme C-terminal region cause progeroid fibrillinopathy. Am J Med Genet A 164A:1341-5
Agarwal, Anil K; Sankella, Shireesha (2014) Phosphatidic acid: a new therapeutic lead to suppress hepatic glucose production. Diabetes Manag (Lond) 4:323-326
Sankella, Shireesha; Garg, Abhimanyu; Horton, Jay D et al. (2014) Hepatic gluconeogenesis is enhanced by phosphatidic acid which remains uninhibited by insulin in lipodystrophic Agpat2-/- mice. J Biol Chem 289:4762-77
Cortés, Víctor A; Cautivo, Kelly M; Rong, Shunxing et al. (2014) Leptin ameliorates insulin resistance and hepatic steatosis in Agpat2-/- lipodystrophic mice independent of hepatocyte leptin receptors. J Lipid Res 55:276-88

Showing the most recent 10 out of 82 publications